Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report

被引:6
|
作者
Thinn, Mie Mie [1 ]
Hsueh, Chung-Tzu [2 ]
Hsueh, Chung-Tsen [3 ]
机构
[1] Loma Linda Vet Adm Med Ctr, Div Hematol & Med Oncol, Loma Linda, CA 92357 USA
[2] Cathay Gen Hosp, Dept Dent, Taipei 106, Taiwan
[3] Loma Linda Univ, Div Med Oncol & Hematol, Dept Med, 11175 Campus St,CSP 11015, Loma Linda, CA 92357 USA
关键词
Squamous cell carcinoma of head and neck; Epidermal growth factor receptor; Erlotinib; Complete response; Skin rash; Tyrosine kinase inhibitor; Case report; GROWTH-FACTOR RECEPTOR; RECURRENT; CANCER; METHOTREXATE; ALPHA;
D O I
10.12998/wjcc.v7.i5.616
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Squamous cell carcinoma of head and neck (SCCHN) is the fifth most common cancer worldwide. Inhibition of epidermal growth factor receptor signaling has been shown to be a critical component of therapeutic option. Herein, we report a case of durable complete response to erlotinib. CASE SUMMARY An 81-year-old Caucasian male who presented with metastatic poorly differentiated squamous cell carcinoma of right cervical lymph nodes (levels 2 and 3). Imaging studies including (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (CT) and contrast-enhanced CT scan of neck and chest did not reveal any other disease elsewhere. Panendoscopic examination with random biopsy did not reveal malignant lesion in nasopharynx, oropharynx, and larynx. He underwent modified neck dissection and postoperative radiation. Within 2 mo after completion of radiation, he developed local recurrence at right neck, which was surgically removed. Two mo after the salvage surgery, he developed a second recurrence at right neck. Due to suboptimal performance status and his preference, he started erlotinib treatment. He achieved partial response after first 2 mo of erlotinib treatment, then complete response after total 6 mo of erlotinib treatment. He developed sever skin rash and diarrhea including Clostridium difficile infection during the course of erlotinib treatment requiring dose reduction and eventual discontinuation. He remained in complete remission for more than two years after discontinuation of erlotinib. CONCLUSION We report a case of metastatic SCCHN achieving durable complete response from erlotinib. Patient experienced skin rash and diarrhea toxicities which were likely predictors of his treatment response.
引用
收藏
页码:616 / 622
页数:7
相关论文
共 50 条
  • [41] Immunotherapy for Head and Neck Squamous Cell Carcinoma
    Moskovitz, Jessica
    Moy, Jennifer
    Ferris, Robert L.
    CURRENT ONCOLOGY REPORTS, 2018, 20 (02)
  • [43] Afatinib in squamous cell carcinoma of the head and neck
    Specenier, Pol
    Vermorken, Jan
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (09) : 1295 - 1301
  • [44] Immunotherapy for Head and Neck Squamous Cell Carcinoma
    Hoesli R.C.
    Moyer J.S.
    Current Oral Health Reports, 2016, 3 (2) : 74 - 81
  • [45] Head and neck squamous cell carcinoma in childhood
    de Carvalho, MB
    Sobrinho, JD
    Rapoport, A
    Fava, AS
    Mendes, AF
    Kanda, JL
    Lehn, CN
    Chacra, J
    Menezes, MB
    Walder, F
    Franzi, SA
    MEDICAL AND PEDIATRIC ONCOLOGY, 1998, 31 (02): : 96 - 99
  • [46] Docetaxel and squamous cell carcinoma of the head and neck
    Calais, G
    BULLETIN DU CANCER, 2004, 91 (02) : 167 - 171
  • [47] Immunotherapy for squamous cell carcinoma of the head and neck
    Yokota, Tomoya
    Homma, Akihiro
    Kiyota, Naomi
    Tahara, Makoto
    Hanai, Nobuhiro
    Asakage, Takahiro
    Matsuura, Kazuto
    Ogawa, Takenori
    Saito, Yuki
    Sano, Daisuke
    Kodaira, Takeshi
    Motegi, Atsushi
    Yasuda, Koichi
    Takahashi, Shunji
    Tanaka, Kaoru
    Onoe, Takuma
    Okano, Susumu
    Imamura, Yoshinori
    Ariizumi, Yosuke
    Hayashi, Ryuichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (10) : 1089 - 1096
  • [48] Angiogenesis in head and neck squamous cell carcinoma
    Homer, JJ
    Greenman, J
    Stafford, ND
    CLINICAL OTOLARYNGOLOGY, 2000, 25 (03): : 169 - 180
  • [49] Retreatment in head and neck squamous cell carcinoma
    Bourhis, J
    DeCrevoisier, R
    Eschwege, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S129 - S130
  • [50] Oligometastasis in Head and Neck Squamous Cell Carcinoma
    Moon, Dominic H.
    Sher, David J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (04): : 803 - 811